Keryx Biopharmaceuticals (NASDAQ:KERX) Getting Somewhat Positive Press Coverage, Analysis Shows

News stories about Keryx Biopharmaceuticals (NASDAQ:KERX) have been trending somewhat positive recently, Accern Sentiment Analysis reports. The research firm identifies negative and positive press coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Keryx Biopharmaceuticals earned a daily sentiment score of 0.02 on Accern’s scale. Accern also gave media coverage about the biopharmaceutical company an impact score of 46.5539327268736 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.

Here are some of the news headlines that may have effected Accern Sentiment Analysis’s rankings:

Shares of Keryx Biopharmaceuticals (NASDAQ:KERX) traded down $0.04 during midday trading on Thursday, reaching $4.54. The company’s stock had a trading volume of 1,594,500 shares, compared to its average volume of 1,535,933. The company has a current ratio of 4.46, a quick ratio of 3.76 and a debt-to-equity ratio of 13.95. Keryx Biopharmaceuticals has a 12 month low of $4.47 and a 12 month high of $8.38.

Keryx Biopharmaceuticals (NASDAQ:KERX) last issued its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.20) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.17) by ($0.03). Keryx Biopharmaceuticals had a negative return on equity of 10,954.62% and a negative net margin of 323.92%. The company had revenue of $15.00 million for the quarter, compared to analysts’ expectations of $18.88 million. During the same quarter last year, the company earned ($0.39) EPS. Keryx Biopharmaceuticals’s revenue for the quarter was up 138.1% compared to the same quarter last year. research analysts expect that Keryx Biopharmaceuticals will post -1.36 earnings per share for the current fiscal year.

A number of equities analysts have weighed in on the company. Zacks Investment Research lowered Keryx Biopharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, September 8th. ValuEngine lowered Keryx Biopharmaceuticals from a “hold” rating to a “sell” rating in a research note on Thursday, September 21st. BidaskClub raised Keryx Biopharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday, August 16th. Finally, Stifel Nicolaus decreased their price target on Keryx Biopharmaceuticals from $7.00 to $5.00 and set a “hold” rating on the stock in a research note on Wednesday, November 8th. One analyst has rated the stock with a sell rating, six have assigned a hold rating and one has issued a buy rating to the company. Keryx Biopharmaceuticals has an average rating of “Hold” and a consensus price target of $7.35.

ILLEGAL ACTIVITY NOTICE: This report was originally reported by The Lincolnian Online and is owned by of The Lincolnian Online. If you are accessing this report on another site, it was stolen and republished in violation of United States & international copyright & trademark law. The original version of this report can be viewed at

Keryx Biopharmaceuticals Company Profile

Keryx Biopharmaceuticals, Inc is a biopharmaceutical company focused on the development of medicines for people with renal disease. The Company is engaged in the manufacture, development and commercialization of products for use in treating human diseases. Its marketed product, Auryxia (ferric citrate), which is an orally available, absorbable, iron-based medicine is approved in the United States for the control of serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis.

Insider Buying and Selling by Quarter for Keryx Biopharmaceuticals (NASDAQ:KERX)

Receive News & Ratings for Keryx Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Keryx Biopharmaceuticals and related companies with's FREE daily email newsletter.

Leave a Reply